Brooks Moore & Associates’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
Other funds holding LLY
VCM
VPM
Brooks Moore & Associates's LLY Position: Q1 2026 in Review
Brooks Moore & Associates reduced its Eli Lilly (LLY) stake by 7.1% in Q1 2026, selling an estimated $203K and leaving 2,624 shares worth $2.41M. The position accounts for 1.21% of the portfolio, ranked #28.
Brooks Moore & Associates first reported a position in LLY in Q4 2018 and has held it in 30 quarters since. The position peaked at $3.55M in Q2 2024. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Brooks Moore & Associates held 2,624 shares of Eli Lilly worth $2.41M as of Q1 2026.
- Brooks Moore & Associates sold 200 Eli Lilly shares in Q1 2026, an estimated $203K.
- Eli Lilly made up 1.21% of Brooks Moore & Associates's portfolio in Q1 2026, its #28 holding.
- Brooks Moore & Associates first reported a position in Eli Lilly in Q4 2018 and has held it in 30 quarters since.
- Brooks Moore & Associates's Eli Lilly position peaked at $3.55M in Q2 2024.
- 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Brooks Moore & Associates's 13F filing for Q1 2026, filed 15 May 2026.